Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Alexander B. Stillebroer"'
Autor:
Rosa L. Coolen, Jan Groen, Alexander B. Stillebroer, Jeroen R. Scheepe, Lambertus P.W. Witte, Bertil F.M. Blok
Publikováno v:
Neuromodulation. Wiley-Blackwell Publishing Ltd
Objectives: The aims of this study were to 1) determine the success rate of the tined lead test phase in patients with nonobstructive urinary retention (NOUR), 2) determine predictive factors of a successful test phase in patients with NOUR, and 3) d
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 163
Syphilis (lues) is a sexually transmitted infection caused by the spirochete Treponema pallidum. In adolescents, the diagnosis of primary syphilis can be made promptly by taking a sexual medical history and inspecting the glans penis.A 17-year-old ma
Autor:
Peter F.A. Mulders, Marye J Boers-Sonderen, Egbert Oosterwijk, Mirjam de Weijert, Alexander B. Stillebroer, Carla M.L. van Herpen, Otto C. Boerman, Johan F. Langenhuijsen, Wim J.G. Oyen, William P.J. Leenders, Ingrid M.E. Desar, Constantijn H.J. Muselaers
Publikováno v:
The Journal of Nuclear Medicine (1978), 55, 242-7
The Journal of Nuclear Medicine (1978), 55, 2, pp. 242-7
The Journal of Nuclear Medicine (1978), 55, 2, pp. 242-7
Item does not contain fulltext Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the chroni
Autor:
Hartwig Huland, Martijn P.M.Q. van Gils, Clément-Claude Abbou, Laurence Bastien, Arnulf Stenzl, Mesut Remzi, Susan Feyerabend, Alexandre de la Taille, Alexander B. Stillebroer, Martina Tinzl, Alexander Haese, Jack A. Schalken, Hendrik Van Poppel, Peter F.A. Mulders, Michael Marberger, Guillaume Ploussard
Publikováno v:
BJU International. 106:1143-1147
Study Type – Diagnosis (exploratory cohort) Level of Evidence 2b OBJECTIVE To determine the performance characteristics of the prostate cancer gene 3 (PCA3) score on the outcome of biopsy relative to different ranges of free-to-total prostate-speci
Autor:
Egbert Oosterwijk, Alexander B. Stillebroer, Otto C. Boerman, Wim J.G. Oyen, Peter F.A. Mulders
Publikováno v:
European Urology, 58, 1, pp. 75-83
European Urology, 58, 75-83
European Urology, 58, 75-83
Contains fulltext : 88192.pdf (Publisher’s version ) (Closed access) CONTEXT: The clinical management of patients with renal cell carcinoma (RCC) remains difficult, and the development of new diagnostic, prognostic, and therapeutic tools is still r
Autor:
Alexander B. Stillebroer, Egbert Oosterwijk, Peter F.A. Mulders, Wim J.G. Oyen, Otto C. Boerman
Publikováno v:
Cancer Imaging
Renal cell carcinoma (RCC) is a radio- and chemotherapy resistant tumor, which has a very high morbidity and mortality when metastasized. The current treatment options demonstrate limited efficacy and severe side-effects. Therefore, there is a need f
Autor:
Alexander B. Stillebroer, Peter F.A. Mulders, Egbert Oosterwijk, Peter Smith-Jones, Ingrid M.E. Desar, Marije J. Boers-Sonderen, Johannes F. Langenhuijsen, Wim J.G. Oyen, Otto C. Boerman, Carla M.L. van Herpen
Publikováno v:
European Urology, 64, 478-85
European Urology, 64, 3, pp. 478-85
European Urology, 64, 3, pp. 478-85
Item does not contain fulltext BACKGROUND: Patients with metastatic clear cell renal cell carcinoma (ccRCC) have a dismal prognosis. Therefore, new and less toxic treatments are needed. OBJECTIVE: We determined the maximum tolerated dose (MTD) and po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05ab0604580abafd9c7e778f84951f3f
http://hdl.handle.net/2066/117417
http://hdl.handle.net/2066/117417
Autor:
Alexander B. Stillebroer, Peter F.A. Mulders, Egbert Oosterwijk, Gerben M. Franssen, Otto C. Boerman, Guus A.M.S. van Dongen, Wim J.G. Oyen, Peter Laverman
Publikováno v:
Stillebroer, A B, Franssen, G M, Mulders, P F A, Oyen, W J G, van Dongen, G A M S, Laverman, P, Oosterwijk, E & Boerman, OC 2013, ' ImmunoPET Imaging of Renal Cell Carcinoma with I-124-and Zr-89-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice ', Cancer Biotherapy and Radiopharmaceuticals, vol. 28, no. 7, pp. 510-515 . https://doi.org/10.1089/cbr.2013.1487
Cancer Biotherapy & Radiopharmaceuticals, 28, 7, pp. 510-5
Cancer Biotherapy & Radiopharmaceuticals, 28, 510-5
Cancer Biotherapy and Radiopharmaceuticals, 28(7), 510-515. Mary Ann Liebert Inc.
Cancer Biotherapy & Radiopharmaceuticals, 28, 7, pp. 510-5
Cancer Biotherapy & Radiopharmaceuticals, 28, 510-5
Cancer Biotherapy and Radiopharmaceuticals, 28(7), 510-515. Mary Ann Liebert Inc.
Item does not contain fulltext Abstract Introduction: Monoclonal antibody (mAb) cG250 recognizes carbonic anhydrase IX (CAIX), overexpressed on clear cell renal cell carcinoma (ccRCC). (124)I-cG250 is currently under clinical investigation for the de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda94a534779c41452a2971b89d8008a
https://research.vumc.nl/en/publications/b3b9d8fb-598a-45c1-b83b-9f56a2d61bb3
https://research.vumc.nl/en/publications/b3b9d8fb-598a-45c1-b83b-9f56a2d61bb3
Autor:
Felix K.H. Chun, Alexander Haese, Alexandre de la Taille, Henk van Poppel, Michael Marberger, Peter F.A. Mulders, Clemens C. Abbou, Alexander B. Stillebroer, Martijn P.M.Q. Van Gils, Jack A. Schalken, Arnulf Stenzl, Yves Fradet, Leonard S. Marks, W. Ellis, Alan W. Partin, Jochen Walz, Marco Auprich
Publikováno v:
Journal of Urology. 187
Autor:
Martin P.M.Q. van Gils, Jens Hansen, Marco Auprich, Felix K.-H. Chun, Karl Pummer, Hartwig Huland, Jack A. Schalken, Alexander B. Stillebroer, Alexander Haese, Arnulf Stenzl, William J. Ellis, Yves Fradet, Alan W. Partin, Peter F.A. Mulders, Alexandre de la Taille, Leonard S. Marks, Hendrik Van Poppel, Clément-Claude Abbou, Michael Marberger
Publikováno v:
Journal of Urology. 187